O
PRGO icon

OrbiMed’s Perrigo PRGO Stock Holding History

OrbiMed’s Portfolio PRGO Stock Details PRGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$7.73M – 143
2014
Q1 		$7.73M Sell
50,000
-125,000
-71% -$19.7M 0.1% 102
2013
Q4 		$26.9M Buy
175,000
+108,600
+164% +$15.7M 0.39% 53
2013
Q3 		$8.19M Buy
+66,400
New +$8.29M 0.15% 86

Other funds holding PRGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OrbiMed's PRGO Position: Q2 2015 in Review

OrbiMed sold out of Perrigo (PRGO) in Q2 2015, closing a stake of 1,247,800 shares — an estimated $207M sold.

OrbiMed first reported a position in PRGO in Q4 2013 and held it in 6 quarters. The position peaked at $209M in Q4 2014. 577 funds tracked by Wall St. Rank hold PRGO as of Q2 2015.

  • OrbiMed reported no remaining Perrigo position as of Q2 2015 after selling out during the quarter.
  • OrbiMed sold 1,247,800 Perrigo shares in Q2 2015, an estimated $207M.
  • OrbiMed first reported a position in Perrigo in Q4 2013 and held it in 6 quarters.
  • OrbiMed's Perrigo position peaked at $209M in Q4 2014.
  • 577 funds tracked by Wall St. Rank held Perrigo as of Q2 2015.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.